Later, individuals with germline p53 missense mutations (Li–Fraumeni Syndrome) were found to have earlier cancer onset and shorter survival compared to those with germline p53 null mutants [76,77]; these findings were supported by similar observations in animal models [78]. The gene discussed is TP53; the disease is cancer.